m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01397)
Name
AMP-PNP
Synonyms
Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; phosphoaminophosphonic acid-adenylate ester; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine; Phosphoaminophosphonic Acid-Adenylate Ester
    Click to Show/Hide
Status
Investigative
Structure
Formula
C10H17N6O12P3
InChI
1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7-,10-/m1/s1
InChIKey
PVKSNHVPLWYQGJ-KQYNXXCUSA-N
PubChem CID
33113
TTD Drug ID
D00ICA
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
DNA repair protein RAD51 homolog 1 (RAD51)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary DNA repair protein RAD51 homolog 1 (RAD51) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of DNA repair protein RAD51 homolog 1 (RAD51). [1], [2]
Ephrin type-A receptor 2 (EPHA2)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for AMP-PNP. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [3], [4]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for AMP-PNP. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [3], [4]
Ephrin type-B receptor 2 (EPHB2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [6]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [6], [7]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [6], [8]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [6], [8]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [6], [9]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [6], [8]
Glycogen synthase kinase-3 beta (GSK-3B)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AMP-PNP. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AMP-PNP through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [10], [11]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AMP-PNP. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMP-PNP through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [11], [12]
Insulin-like growth factor I receptor (IGF1R)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [13], [14]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [14], [15]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [14], [16]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [14], [17]
References
Ref 1 METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis. Elife. 2022 May 3;11:e75231. doi: 10.7554/eLife.75231.
Ref 2 National Cancer Institute Drug Dictionary (drug name CYT0851).
Ref 3 m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022 May 21;13(5):483. doi: 10.1038/s41419-022-04950-2.
Ref 4 Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. doi: 10.4161/cbt.10.12.13582. Epub 2010 Dec 15.
Ref 5 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.
Ref 6 Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13. doi: 10.1074/jbc.M706340200. Epub 2007 Sep 26.
Ref 7 hnRNPA2B1 Promotes Colon Cancer Progression via the MAPK Pathway. Front Genet. 2021 Sep 22;12:666451. doi: 10.3389/fgene.2021.666451. eCollection 2021.
Ref 8 Dynamic m(6)A mRNA Methylation Reveals the Role of METTL3/14-m(6)A-MNK2-ERK Signaling Axis in Skeletal Muscle Differentiation and Regeneration. Front Cell Dev Biol. 2021 Oct 1;9:744171. doi: 10.3389/fcell.2021.744171. eCollection 2021.
Ref 9 Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 2021 Jun 4;49(10):5779-5797. doi: 10.1093/nar/gkab415.
Ref 10 Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5. Front Cardiovasc Med. 2020 Nov 20;7:592550. doi: 10.3389/fcvm.2020.592550. eCollection 2020.
Ref 11 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J Med Chem. 2004 Sep 9;47(19):4716-30. doi: 10.1021/jm040063i.
Ref 12 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 13 IGF2BP2 promotes gastric cancer progression by regulating the IGF1R-RhoA-ROCK signaling pathway. Cell Signal. 2022 Jun;94:110313. doi: 10.1016/j.cellsig.2022.110313. Epub 2022 Mar 16.
Ref 14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 15 m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med. 2021 Jun;11(6):e426. doi: 10.1002/ctm2.426.
Ref 16 ALKBH5 regulates IGF1R expression to promote the Proliferation and Tumorigenicity of Endometrial Cancer. J Cancer. 2020 Jul 25;11(19):5612-5622. doi: 10.7150/jca.46097. eCollection 2020.
Ref 17 m(6)A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis. Front Oncol. 2020 Jul 31;10:1166. doi: 10.3389/fonc.2020.01166. eCollection 2020.